Edwards Lifesciences (NYSE:EW – Get Free Report) updated its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.740. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on EW shares. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. Barclays reissued an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Royal Bank Of Canada increased their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.95.
View Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Stock Performance
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,577 shares of company stock worth $3,855,527 in the last quarter. 0.31% of the stock is currently owned by company insiders.
Institutional Trading of Edwards Lifesciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its stake in shares of Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after acquiring an additional 371,892 shares during the last quarter. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after purchasing an additional 989,533 shares during the last quarter. Morgan Stanley boosted its holdings in Edwards Lifesciences by 12.4% in the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after purchasing an additional 804,942 shares during the period. Marshall Wace LLP grew its position in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
